Skip to main content
XORTX Therapeutics Inc. logo

XORTX Therapeutics Inc. — Investor Relations & Filings

Ticker · XRTX ISIN · CA98420Q2071 LEI · 254900RAT3XZPF9F9350 US Manufacturing
Open in API
Filings indexed 263 across all filing types
Latest filing 2024-06-13 Interim / Quarterly Rep…
Country CA Canada
Listing US XRTX

About XORTX Therapeutics Inc.

https://www.xortx.com/

XORTX Therapeutics Inc. is a late-stage clinical biopharmaceutical company that develops and commercializes therapies for diseases associated with aberrant purine metabolism and high serum uric acid. The company's pipeline focuses on progressive kidney diseases, including Autosomal Dominant Polycystic Kidney Disease (ADPKD), Type 2 Diabetic Nephropathy (T2DN), and Acute Kidney Injury (AKI), as well as gout. Its lead program, XRx-008, is in development for the treatment of ADPKD.

Recent filings

Filing Released Lang Actions
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed by XORTX Therapeutics Inc., which includes condensed interim consolidated financial statements for the three and nine months ended September 30, 2023 and 2022. It contains detailed financial data such as statements of financial position, comprehensive loss, changes in shareholders' equity, and cash flows, along with management discussion and analysis and CEO and CFO certificates. The presence of unaudited interim financial statements and management discussion for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document is not merely an announcement or certification but contains substantive financial data and analysis for the interim period. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2024-06-13 English
424B3
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document includes a Prospectus Supplement related to a share issuance, a Form 6-K filing by a foreign private issuer, and a detailed Report of Voting Results from a Special Meeting of Shareholders. The key content is the voting results on a share consolidation resolution, with detailed vote counts and references to meeting materials. The presence of a 'Report of Voting Results' as Exhibit 99.1 and the detailed voting outcome indicates this document is primarily about the official results of shareholder votes. Therefore, the document fits the category 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length and content are consistent with a voting results report rather than a brief announcement or a full annual report or prospectus. Hence, the classification is DVA with high confidence.
2024-06-13 English
424B3
Share Issue/Capital Change Classification · 95% confidence The document is a Form 6-K filed by XORTX Therapeutics Inc., which is a report of a foreign private issuer pursuant to SEC rules. It includes a Prospectus Supplement related to the issuance of common shares upon exercise of warrants, a Notice of Special Meeting of Shareholders, a Management Information Circular, and proxy solicitation materials. The content focuses on shareholder meeting notices, proxy information, and capital structure changes (share consolidation). There are no financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is primarily about shareholder meeting materials and capital changes, specifically a share consolidation proposal. This fits best under the category of Share Issue/Capital Change (SHA), as it involves amendments to articles for share consolidation and issuance of shares upon warrant exercise. The document is substantive and not merely an announcement or a proxy solicitation alone, but includes detailed information about capital changes and shareholder voting related to those changes. Therefore, the classification is SHA with high confidence.
2024-06-13 English
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed by XORTX Therapeutics Inc., which includes condensed interim consolidated financial statements for the three months ended March 31, 2024, along with management discussion and analysis, and CEO and CFO certificates. The presence of unaudited financial statements for a quarter, detailed financial data, and management commentary indicates this is an interim or quarterly report. The document is not merely an announcement or a certification but contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2024-06-13 English
424B3
Annual Report Classification · 100% confidence The document is a Form 20-F filed with the SEC, which is an annual report for a foreign private issuer. It is explicitly titled as an "Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934" for the fiscal year ended December 31, 2023. The text includes detailed sections typical of an annual report such as risk factors, financial statements, management discussion, and corporate governance. The document length is substantial (15,000 characters), indicating it contains the full report rather than just an announcement. Therefore, this filing is classified as an Annual Report (10-K equivalent for foreign issuers).
2024-06-13 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing by XORTX Therapeutics Inc., which includes a Prospectus Supplement related to an at-the-market offering of common shares, legal opinion letters, and an offering agreement. The content focuses on amendments and supplements to a prospectus, legal opinions on share issuance, and agreements related to capital raising activities. There are no financial statements or quarterly/yearly performance data presented. The document is primarily about financing activities and capital structure changes through share issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is not a mere announcement but a detailed filing related to financing.
2024-06-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.